Alector Quote - ALEC

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

3.505

Bid

3.50

Ask

3.51

Volume

156,572

3.49 Day's Range 3.675

3.49 52 Week Range 8.90

Market Cap

343.254M

Previous Close

3.635

Open

3.65

Last Trade

100

3.505

Last Trade Time

09:49:12

Financial Volume

US$ 556,792

VWAP

3.5561

Average Volume (3m)

596,452

Shares Outstanding

97,932,605

Dividend Yield

PE Ratio

-2.64

Earnings Per Share (EPS)

-1.33

Revenue

97.06M

Net Profit

-130.39M

Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to... Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.alector.com

Headquarters

Wilmington, Delaware, USA

Founded

Alector Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALEC. The last closing price for Alector was US$3.64. Over the last year, Alector shares have traded in a share price range of US$ 3.49 to US$ 8.90.

Alector currently has 97,932,605 shares outstanding. The market capitalization of Alector is US$355.99 million. Alector has a price to earnings ratio (PE ratio) of -2.64.

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.655	-32.0736434109	5.16	5.16	3.49	774916	3.95938892	CS
4	-1.195	-25.4255319149	4.7	6.14	3.49	736564	4.92511361	CS
12	-1.795	-33.8679245283	5.3	6.37	3.49	596452	5.04971081	CS
26	-1.875	-34.8513011152	5.38	6.78	3.49	603846	5.10919485	CS
52	-1.295	-26.9791666667	4.8	8.9	3.49	623745	5.73388177	CS
156	-17.8584	-83.5934355018	21.3634	24.005	3.49	618156	8.64900111	CS
260	-12.485	-78.0800500313	15.99	45	3.49	677039	15.03918715	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WORXSCWorx Corporation	US$ 1.94 (97.96%)	99.02M
CRNCCerence Inc	US$ 5.30 (87.94%)	23.7M
SKKSKK Holdings Limited	US$ 7.32 (60.53%)	5.65M
IBGInnovation Beverage Group Limited	US$ 1.26 (59.25%)	4.2M
SURGSurgePays Inc	US$ 2.115 (44.86%)	11.62M
PYXSPyxis Oncology Inc	US$ 2.08 (-45.55%)	8.22M
KURAKura Oncology Inc	US$ 9.9613 (-37.39%)	6.84M
SHOTWSafety Shot Inc	US$ 0.1001 (-33.27%)	2.5k
BLRXBioLineRx Ltd	US$ 0.37 (-32.13%)	4.96M
TMTCTMT Acquisition Corporation	US$ 4.66 (-27.64%)	12.11k
CDTConduit Pharmaceuticals Inc	US$ 0.1156 (25.24%)	463.61M
NVDANVIDIA Corporation	US$ 143.17 (-1.86%)	180.58M
AKTSAkoustis Technologies Inc	US$ 0.1049 (20.44%)	177.49M
ELABElevai Labs Inc	US$ 0.0203 (-5.14%)	115.33M
WORXSCWorx Corporation	US$ 1.9353 (97.48%)	99.94M